Advanced search
Publication Cover
Current Medical Research and Opinion Volume 36, 2020 - Issue 7
Submit an article Journal homepage
154
Views
3
CrossRef citations to date
0
Altmetric
Oncology

First-line endocrine therapy for advanced breast cancer. A real-world study at a Latin American university health institution

Benjamin WalbaumDepartment of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;
,
Francisco AcevedoDepartment of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;
,
Lidia MedinaCentro de cáncer Red Red de Salud UC Christus, Pontificia Universidad Católica de Chile, Santiago, Chile;
,
M. Loreto BravoDepartment of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;
,
Tomas MerinoDepartment of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;
,
Mauricio CamusDepartment of Surgical Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
,
Francisco DominguezDepartment of Surgical Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
,
Sebastian MondacaDepartment of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;
,
Hector GalindoDepartment of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;
,
Bruno NerviDepartment of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;
,
Carolina IbañezDepartment of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;
,
Jorge MadridDepartment of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;
,
Jose PeñaDepartment of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;
,
Erica KochDepartment of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;
,
Marcelo GarridoDepartment of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;
,
Mauricio P. PintoDepartment of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile;
&
César SánchezDepartment of Hematology-Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile; Correspondence[email protected]
 show all
Pages 1195-1199 | Received 17 Dec 2019, Accepted 28 Apr 2020, Published online: 14 May 2020

References

  • Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
  • Sánchez C, Camus M, Medina L, et al. Clinico-pathologic subtypes of breast cancer primary tumors are related to prognosis after recurrence. Asian Pacific J Cancer Prev. 2016;17:5081–5086.
  • Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29(8):1634–1657.
  • Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20(10):1360–1369.
  • Goldschmidt D, Dalal AA, Romdhani H, et al. Current treatment patterns among postmenopausal women with HR+/HER2− metastatic breast cancer in US community oncology practices: an observational study. Adv Ther. 2018;35(4):482–493.
  • Zanotti G, Hunger M, Perkins JJ, et al. Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States. BMC Cancer. 2017;17(1):393.
  • Swallow E, Zhang J, Thomason D, et al. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002–2012. Curr Med Res Opin. 2014;30(8):1537–1545.
  • Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–316.
  • Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline. J Clin Oncol. 2016;34(25):3069–3103.
  • Beslija S, Bonneterre J, Burstein H, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2007;18(2):215–225.
  • Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936.
  • Park YH, Kim TY, Kim GM, et al. A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10, NCT02592746). J Clin Oncol. 2019;37(15_suppl):1007–1007.
  • Beresford M, Tumur I, Chakrabarti J, et al. A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clin Oncol. 2011;23(3):209–215.
  • Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514–524.
  • Eziokwu AS, Varella L, Kruse ML, et al. Real-world evidence evaluating continuation of CDK4/6 inhibitors beyond first progression in hormone receptor-positive (HR+) metastatic breast cancer. J Clin Oncol. 2019;37(15_suppl):e12538–e12538.
  • Waller J, Mitra D, Mycock K, et al. Real-world treatment patterns and clinical outcomes in patients receiving palbociclib for hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer in Argentina: the IRIS study. J Glob Oncol. 2019;5(5):JGO1800239.
  • Bonotto M, Gerratana L, Di Maio M, et al. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis. Breast. 2017;31:114–120.
  • André F, Neven P, Marinsek N, et al. Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Curr Med Res Opin. 2014;30(6):1007–1016.
  • Problemas de Salud - AUGE 85 - Ministerio de Salud [Internet]. Available from: https://auge.minsal.cl/problemasdesalud/index/8.
  • Twelves C, Cheeseman S, Sopwith W, et al. Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre. BMC Cancer. 2020;20(1):53.
  • Jacobs L, Bevers TB, Helvie M, et al. Breast cancer screening and diagnosis, version 3.2018. JNCCN J Natl Compr Cancer Netw. 2018;16:1362–1389.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.